|
1
|
Strandberg TE: Lipid-lowering drugs and
heart failure: Where do we go after the statin trials? Curr Opin
Cardiol. 25:385–393. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Volpe M, Carnovali M and Mastromarino V:
The natriuretic peptides system in the pathophysiology of heart
failure: From molecular basis to treatment. Clin Sci (Lond).
130:57–77. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glezeva N, Horgan S and Baugh JA: Monocyte
and macrophage subsets along the continuum to heart failure:
Misguided heroes or targetable villains? J Mol Cell Cardiol.
89:136–145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Münzel T, Gori T, Keaney JF Jr, Maack C
and Daiber A: Pathophysiological role of oxidative stress in
systolic and diastolic heart failure and its therapeutic
implications. Eur Heart J. 36:2555–2564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shantsila E, Wrigley BJ, Blann AD, Gill PS
and Lip GY: A contemporary view on endothelial function in heart
failure. Eur J Heart Fail. 14:873–881. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brower GL, Gardner JD, Forman MF, Murray
DB, Voloshenyuk T, Levick SP and Janicki JS: The relationship
between myocardial extracellular matrix remodeling and ventricular
function. Eur J Cardiothorac Surg. 30:604–160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin W: Heart failure, can be very special
(N). Zhongguo yi xue lun tan bao Dec. 16:12–14. 2017.(In
Chinese).
|
|
8
|
Freda BJ, Slawsky M, Mallidi J and Braden
GL: Decongestive treatment of acute decompensated heart failure:
Cardiorenal implications of ultrafiltration and diuretics. Am J
Kidney Dis. 58:1005–1017. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz
MM, et al: 2016 ACC/AHA/HFSA Focused update on new pharmacological
therapy for heart failure: An update of the 2013 ACCF/AHA Guideline
for the management of heart failure. A report of the American
College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines and the Heart Failure Society of
America. Circulation. 134:e282–e293. 2016.PubMed/NCBI
|
|
10
|
Babelova A, Sedding DG and Brandes RP:
Anti-atherosclerotic mechanisms of statin therapy. Curr Opin
Pharmacol. 13:260–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Birnbaum Y and Ye Y: Pleiotropic effect of
statins: The role of eicosanoid production. Curr Atheroscler Aep.
14:135–139. 2012. View Article : Google Scholar
|
|
12
|
Wang CY, Liu PY and Liao JK: Pleiotropic
effects of statin therapy: Molecular mechanisms and clinical
results. Trends Mol Med. 14:37–44. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bauersachs J, Galuppo P, Fraccarollo D,
Christ M and Ertl G: Improvement of left ventricular remodeling and
function by hydroxymethylglutaryl coenzyme a reductase inhibition
with cerivastatin in rats with heart failure after myocardial
infarction. Circulation. 104:982–985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayashidani S, Tsutsui H, Shiomi T,
Suematsu N, Kinugawa S, Ide T, Wen J and Takeshita A: Fluvastatin,
a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor,
attenuates left ventricular remodeling and failure after
experimental myocardial infarction. Circulation. 105:868–873. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alehagen U, Benson L, Edner M, Dahlström U
and Lund LH: Association between use of statins and mortality in
patients with heart failure and ejection fraction of ≥50. Circ
Heart Fail. 8:862–870. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wojnicz R, Wilczek K, Nowalany-Kozielska
E, Szyguła-Jurkiewicz B, Nowak J, Poloński L, Dyrbuś K, Badziński
A, Mercik G, Zembala M, et al: Usefulness of atorvastatin in
patients with heart failure due to inflammatory dilated
cardiomyopathy and elevated cholesterol levels. Am J Cardiol.
97:899–904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sola S, Mir MQ, Lerakis S, Tandon N and
Khan BV: Atorvastatin improves left ventricular systolic function
and serum markers of inflammation in nonischemic heart failure. J
Am Coll Cardiol. 47:332–337. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horwich TB, MacLllan R and Fonarow GC:
Statin therapy is associated with improved survival in ischemic and
non-ischemic heart failure. J Am Coll Cardiol. 43:642–648. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ren J and Fang CX: Small guanine
nucleotide-binding protein Rho and myocardial function. Acta
Pharmacologica Sinica. 26:279–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kobayashi N, Horinaka S, Mita S, Nakano S,
Honda T, Yoshida K, Kobayashi T and Matsuoka H: Critical role of
Rho-kinase pathway for cardiac performance and remodeling in
failing rat hearts. Cardiovasc Res. 55:757–767. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kobayashi N, Nakano S, Mita S, Kobayashi
T, Honda T, Tsubokou Y and Matsuoka H: Involvement of Rho-kinase
pathway for angiotensin II-induced plasminogen activator
inhibitor-1 gene expression and cardiovascular remodeling in
hypertensive rats. J Pharmacol Exp Ther. 301:459–466. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Serra N, Rosales R, Masana L and Vallvé
JC: Simvastatin increases Fibulin-2 expression in human coronary
artery smooth muscle cells via RhoA/Rho-Kinase signaling pathway
inhibition. PLoS One. 10:e01338752015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shimokawa H, Sunamura S and Satoh K:
RhoA/Rho-Kinase in the cardiovascular system. Circ Res.
118:352–366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li JZ: Method of determination of blood
lipid recommended by Chinese Society of Laboratory Medicine: Serum
total cholesterol determination by enzymatic method. Zhonghua jian
yan yi xue za zhi. 18:185–187. 1995.(In Chinese).
|
|
25
|
Giovambattista A, Gaillard RC and Spinedi
E: Ghrelin gene-related peptides modulate rat white adiposity.
Vitam Horm. 77:171–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Landmesser U, Engberding N, Bahlmann FH,
Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner
D, Templin C, Kotlarz D, et al: Statin-induced improvement of
endothelial progenitor cell mobilization, myocardial
neovascularization, left ventricular function, and survival after
experimental myocardial infarction requires endothelial nitric
oxide synthase. Circulation. 110:1933–1939. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sauzeau V, Le Jeune H, Cario-Toumaniantz
C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P and
Loirand G: Cyclic GMP-dependent protein kinase signaling pathway
inhibits RhoA-induced Ca2+ sensitization of contraction in vascular
smooth muscle. J Biol Chem. 275:21722–21729. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fleming JE and Paull TT: Semi-dry
electroblotting of DNA. Biotechniques. 6(926): 928–929. 1988.
|
|
29
|
Chappel GI, Rona G, Balazs T and Gaudry R:
Comparison of cardiotoxic actions of certain sympathomimetic
amines. Can J Biochem Physiol. 37:35–42. 1959. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ray S, Jindal AK, Sengupta S and Sinha S:
Statins: Can we advocate them for primary prevention of heart
disease? Med J Armed Forces India. 70:270–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Satoh S, Ueda Y, Koyanagi M, Kadokami T,
Sugano M, Yoshikawa Y and Makino N: Chronic inhibition of Rho
kinase blunts the process of left ventricular hypertrophy leading
to cardiac contractile dysfunction in hypertension-induced heart
failure. J Mol Cell Cardiol. 35:59–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hattori T, Shimokawa H, Higashi M, Hiroki
J, Mukai Y, Tsutsui H, Kaibuchi K and Takeshita A: Long-term
inhibition of Rho-kinase suppresses left ventricular remodeling
after myocardial infarction in mice. Circulation. 109:2234–2239.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong M, Liao JK, Yan B, Li R, Zhang M and
Yu CM: A combination of increased Rho kinase activity and
N-terminal pro-B-type natriuretic peptide predicts worse
cardiovascular outcome in patients with acute coronary syndrome.
Int J Cardiol. 167:2813–2819. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mutlu E, İlhan S, Onat E, Kara M and Şahna
E: The effects of novokinin, an AT2 agonist, on blood pressure,
vascular responses, and levels of ADMA, NADPH oxidase, and Rho
kinase in hypertension induced by NOS inhibition and salt. Turk J
Med Sci. 46:1249–1257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mossion PB and Balligand JL: Modulation of
cardiac contraction, relaxation and rate by the endothelial
nitricoxide synthase (eNOS): Lessons from genetically modified
mice. J Physiol. 546:63–75. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koyanagi M, Egashira K, Kitamoto S, Ni W,
Shimokawa H, Takeya M, Yoshimura T and Takeshita A: Role of
monocyte chemoattractant protein-1 in cardiovascular remodeling
induced by chronic blockade of nitric oxide synthesis. Circulation.
102:2243–2248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Talukder MA, Fujiki T, Morikawa K,
Motoishi M, Matsuo Y, Hatanaka M, Tsutsui M, Takeshita A and
Shimokawa H: Endothelial nitric oxide synthase-independent effects
of an ACE inhibition on coronary flow response to bradykinin in
aged mice. J Cardiovasc Pharmacol. 44:557–563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Laufs U, Endres M, Stagliano N,
Amin-Hanjani S, Chui DS, Yang SX, Simoncini T, Yamada M, Rabkin E,
Allen PG, et al: Neuroprotection mediated by changes in the
endothelial actin cytoskeleton. J Clin Invest. 106:15–24. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Endo A, Tsujita Y, Kuroda M and Tanzawa K:
Effects of ML-236B on cholesterol metabolism in mice and rats: Lack
of hypocholesterolemic activity in normal animals. Biochim Biophys
Acta. 575:266–276. 1979. View Article : Google Scholar : PubMed/NCBI
|
